4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Haematologica, Vol 95, Issue 2, 311-319 doi:10.3324/haematol.2009.012674
Copyright © 2010 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Mohty, B.
Right arrow Articles by Mohty, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohty, B.
Right arrow Articles by Mohty, M.

Multiple Myeloma

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

Bilal Mohty1, Jean El-Cheikh2, Ibrahim Yakoub-Agha3, Philippe Moreau4,5, Jean-Luc Harousseau5,6, Mohamad Mohty4,5

1 Service d’Hématologie, Hopital Universitaire de Genève, Geneva, Switzerland
2 Département d’Hématologie, Institut Paoli-Calmettes, Marseille, France
3 Service des Maladies du Sang, CHRU de Lille, Lille, France
4 Service d’Hématologie Clinique, CHU de Nantes, Hôpital Hôtel-Dieu, Nantes, France
5 Université de Nantes and INSERM UMR 892, Nantes, France
6 Centre Régional de Lutte Contre le Cancer (CRLCC) René Gauducheau, Nantes, France

Correspondence: Mohamad Mohty, MD, PhD, Service d’Hématologie Clinique, Hôpital Hôtel-Dieu, CHU de Nantes, Place Alexis Ricordeau, 44093 Nantes Cedex, France. E-mail: mohamad.mohty{at}univ-nantes.fr

In multiple myeloma, peripheral neuropathy has for a long time been considered as mainly secondary to the plasma cell dyscrasia itself. With the advent of new targeted drugs such as thalidomide and bortezomib, the iatrogenic neurotoxicity has become the leading cause of peripheral neuropathy. This review discusses the pathogenesis, incidence, risk factors, diagnosis, characteristics, and management of peripheral neuropathy related to new multiple myeloma drugs, mainly bortezomib and thalidomide. The current knowledge of the pathophysiology of the new forms of peripheral neuropathy is still limited. The mechanisms involved depend on the agents used, patient’s medical history, and duration of exposure and/or treatment doses or sequence. Diagnosis of such peripheral neuropathy is often easier than treatment. A full anamnesis and regular clinical evaluation are necessary. Electrophysiological assessments may support the diagnosis, although their contribution remains insufficient. Complex clinical features may require a specialized neurological assessment within the context of a multi-disciplinary approach. Finally, early detection of peripheral neuropathy and the use of dose adjustment algorithms as in the case of bortezomib, should help reduce the side effects while maintaining anti-tumor efficacy.

Key words: peripheral neuropathy, multiple myeloma, practical recommendations.